Online Seminar: FDA’s Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering (July 18-19, 2019) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “FDA’s Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering” training has been added to ResearchAndMarkets.com’s offering.

This Seminar will provide a historical context for the use of stem cells in medicine, where the field has been and where it is going. It will also provide a few examples of FDA approved the use of stem cells in medicine and what is needed for the field to progress. Learn the fundamentals of stem cells and the FDA’s regulatory approach for its use in medicine.

Stem cells harness the power to differentiate into numerous cells upon stimulation. This has led to their wide exploration across all of medicine, including high-risk diseases. Of course, significant scientific breakthroughs in the use of stem cells to prevent, diagnose, and treat numerous diseases has caused numerous start-up companies to form.

Despite, such promise, the FDA has yet to approve stem cell therapies for a wide range of diseases, except cord blood-derived hematopoietic progenitor cells for certain indications. Attend this seminar to learn and apply the definitive ways to needed for the field to progress.

Learning Objectives:

Upon completing this course participants should have an understanding of:

  • Fundamentals of stem cells

    • How to control stem cell differentiation
    • Sources of stem cells
    • Incorporating stem cells into biomaterials
    • Avoiding immune system clearance of stem cells
  • FDA regulatory approach for the use of stem cells in medicine

    • Currently approved/accepted uses of stem cells in medicine
    • FDA guidance documents for stem cell technologies
    • Global approval of stem cell technologies (emphasis on EMA, Japan, China, India and Canada)
    • How the FDA regulates regenerative treatments and therapies
    • The use of human cells, tissues, and cellular and tissue-based (HCT/P) products and the FDA’s regulatory framework
    • Use of non-HCT/P therapeutic materials (e.g., PRP and BMC) in the US
    • The drug and biological approval process
    • Regenerative products as medical devices
    • How to design appropriate clinical trials with an emphasis on stem cell-based materials
    • Applicable good manufacturing and good laboratory practices
    • Product labelling, marketing and advertising
    • FDA and other federal agency enforcement action
  • Future thoughts on approaches for regulatory approval of stem cell technologies

    • Remaining hurdles
    • Outlook for new technologies

Key Topics Covered:

Day 01 (5:00 AM – 1:00 PM)

Fundamentals of stem cells

  • Definitions
  • What is all the excitement about
  • How to control stem cell differentiation
  • Sources of stem cells
  • Incorporating stem cells into biomaterials
  • Avoiding immune system clearance of stem cells
  • Research examples pre-clinical approval
  • Research examples post-clinical approval
  • FDA regulatory approvals for the use of stem cells in medicine
  • Currently approved the use of stem cells in medicine
  • FDA guidance documents for stem cell technologies
  • Global approval of stem cell technologies

Day 02 (5:00 AM – 1:00 PM)

FDA regulatory approvals for the use of stem cells in medicine

  • How the FDA regulates regenerative treatments and therapies
  • The use of human cells, tissues, and cellular and tissue-based product criteria and Minimal Manipulation Standard
  • The drug and biological approval process
  • Regenerative products as medical devices
  • How to design appropriate clinical trials
  • Applicable good manufacturing and good laboratory practices
  • Product labelling, marketing and advertising
  • FDA and other federal agency enforcement action
  • Future thoughts on approaches for regulatory approval of stem cell technologies
  • Remaining hurdles
  • Outlook for new technologies
  • Strategies for commercializing stem cell technologies
  • Questions

For more information about this training visit https://www.researchandmarkets.com/r/m5u7fu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics: Biopharmaceuticals, Stem Cells, Biomaterials